Delirium and High Creatine Kinase and Myoglobin Levels Related to Synthetic Cannabinoid Withdrawal
Open Access
- 10 April 2017
- journal article
- case report
- Published by Wiley in Case Reports in Medicine
- Vol. 2017, 1-6
Abstract
Synthetic cannabinoids (SCs) are included in a group of drugs called new psychoactive substances. Effects of SCs on the central nervous system are similar to other cannabinoids, but 2–100 times more potent than marijuana. Thus, addiction and withdrawal symptoms are more severe than natural cannabinoids. Withdrawal symptoms of SCs were reported in the literature previously. But there is no report about SC withdrawal delirium and its treatment. Several studies reported that agonists of CB1 receptors play a role in GABA and glutamatergic neurotransmission, which is similar to the effects of alcohol on GABA and glutamatergic receptors. Previous studies on alcohol delirium cases suggested that elevated creatine kinase (CK) can be a marker of progress. This study reports delirium and high serum CK levels related to SC withdrawal and offers a treatment with benzodiazepine for them. We described two cases treated in our inpatient clinic about SC withdrawal with increase of serum CK level and other laboratory parameters. One of them demonstrated delirium symptoms and the other did not with early rapid treatment.Keywords
This publication has 21 references indexed in Scilit:
- Adverse Effects of Synthetic Cannabinoids: Management of Acute Toxicity and WithdrawalCurrent Psychiatry Reports, 2016
- Synthetic cannabinoids: Epidemiology, pharmacodynamics, and clinical implicationsDrug and Alcohol Dependence, 2014
- Review of detection frequency and type of synthetic cannabinoids in herbal compounds analyzed by Istanbul Narcotic Department of the Council of Forensic Medicine, TurkeyJournal of Forensic and Legal Medicine, 2013
- Synthetic Cannabinoid Intoxication: A Case Series and ReviewThe Journal of Emergency Medicine, 2013
- The Central Amygdala and Alcohol: Role of -Aminobutyric Acid, Glutamate, and NeuropeptidesCold Spring Harbor Perspectives in Medicine, 2012
- Beyond THC: The New Generation of Cannabinoid Designer DrugsFrontiers in Behavioral Neuroscience, 2011
- Pharmacology, Signaling and Physiological Relevance of the G Protein-coupled Receptor 552011
- Molecular biology of cannabinoid receptorsProstaglandins, Leukotrienes and Essential Fatty Acids, 2002
- Novel cannabinoid-sensitive receptor mediates inhibition of glutamatergic synaptic transmission in the hippocampusNeuroscience, 2001
- GENERAL PHARMACOLOGICAL ACTIONS OF SOME SYNTHETIC TETRAHYDROCANNABINOL DERIVATIVESPharmacological Reviews, 1971